Erste Asset Management GmbH Sells 4,661 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Erste Asset Management GmbH trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,736 shares of the biopharmaceutical company’s stock after selling 4,661 shares during the quarter. Erste Asset Management GmbH’s holdings in Regeneron Pharmaceuticals were worth $27,329,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter worth about $38,000. Berbice Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 5,274 shares of company stock worth $4,142,738. Insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on REGN shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Finally, Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Regeneron Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:REGN opened at $770.79 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market cap of $81.49 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.11 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company’s 50-day moving average price is $771.32 and its two-hundred day moving average price is $679.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $12.07 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.